The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency
Open accessAbstract
PURPOSE: IgPro20, Hizentra(®) an L-proline-stabilized 20% human subcutaneous immunoglobulin (SCIG), has been shown in a Phase III pivotal study to be well tolerated and efficacious in adult and pediatric Japanese patients with primary immunodeficiency. Economic aspects of SCIG treatment in comparison with previous intravenous immunoglobulin (IVIG) therapy were analyzed in this Phase III study in Japan. METHODS: Twenty-four Japanese patients with primary immunodeficiency on IVIG treatment were switched to IgPro20 at an equivalent dose (full analysis set). The study consisted of a screening period, an IVIG treatment period with 3 planned infusions every 3 or 4 weeks, a 12-week SCIG wash-in and wash-out period, and a 12-week SCIG efficacy period. The difference in medical cost and productivity loss resulting from changes in hospital frequency between the SCIG and IVIG treatment was evaluated. Information about treatment cost was collected as part of the Life Quality Index questionnaire. In addition, productivity loss and hospital-related absenteeism were evaluated. FINDINGS: Life Quality Index scores for all domains were higher with SCIG than with IVIG in this patient population. In the full analysis set, the mean (SD) Life Quality Index score of the Costs domain increased from 45.1 (26.34) at Week 1 (IVIG period) to 71.9 (18.52) at Week 24 (end of the SCIG efficacy period), representing a mean change of 26.74 and a large score improvement effect size (1.01). Median productivity loss was reduced by 60% from baseline to Weeks 12 and 24. This resulted in a reduction in costs of JPY 10,875 per patient per month at Weeks 12 and 24. Subcutaneous treatment with IgPro20 also reduced hospital-related absenteeism. The number of patients, parents, or guardians who were not absent from work or housework duties and had no reduction in working time increased from 4 (17.4%) at Week 1 to 9 (39.1%) at Week 24. Similar results were obtained in the per-protocol set (n = 21). IMPLICATIONS: Switching from IVIG to SCIG reduced markedly productivity loss and hospital-related absenteeism. The reduction in hospital visit frequency due to the use of home-based IgG therapy enabled by the change in administration route is expected to produce an important pharmacoeconomic benefit in Japan. Study Code: ZLB06_002CR, ClinicalTrials.gov identifier: NCT01199705.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Index scores for all domains were higher with SCIG than with IVIG.
“Index scores for all domains were higher with SCIG than with IVIG [58].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [58]
The reduction in productivity loss resulted in a reduction in costs of ¥10,875 per patient per month at weeks 12 and 24.
“Productivity loss was reduced by 60% from baseline at weeks 12 and 24, which resulted in a reduction in costs of ¥10,875 per patient per month at weeks 12 and 24.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [58]
Productivity loss was reduced by 60% from baseline at weeks 12 and 24.
“Productivity loss was reduced by 60% from baseline at weeks 12 and 24, which resulted in a reduction in costs of ¥10,875 per patient per month at weeks 12 and 24.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [58]
Subcutaneous dosing markedly reduced hospital-related absenteeism, with the number of patients and caregivers not absent from work or housework duties and with no reduction in working time increasing from four (17.4%) at week 1 to nine (39.1%) at week 24.
“Subcutaneous dosing markedly reduced hospital-related absenteeism, with the number of patients and caregivers not absent from work or housework duties and with no reduction in working time increasing from four (17.4%) at week 1 to nine (39.1%) at week 24.”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Methods for the economic evaluation of health care programmes, 3rd ed
Adamiak, G. T. (2006) · PubMed Central · Cited by 953
Al–Herz, W., Bousfiha, A. A., Casanova, J., Chatila, T. A., Conley, M. E., Cunningham‐Rundles, C., Etzioni, A., Franco, J. L., Gaspar, H. B., Holland, S. M., et al. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00162 · Cited by 769
Geha, R. S., Notarangelo, L. D., Casanova, J., Chapel, H. M., Conley, M. E., Fischer, A., Hammarström, L. L. G., Nonoyama, S., Ochs, H. D., Puck, J. M., et al. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.08.053 · Cited by 553
The Use of Intravenous Immune Globulin in Immunodeficiency Diseases
Oates, J. A., Wood, A. J. J., Buckley, R. H., & Schiff, R. I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107113250207 · Cited by 308
Rn, A. G., Hammarström, L. L. G., Gustafson, R., Nyström, T., Smith, C. I. E., Gustafson, R., Jonsson, E. L., Gardulf, A., Jonsson, E. L., Möller, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90346-1 · Cited by 266
Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion
Hammarström, L. L. G., Gardulf, A., Smith, C. I. E., & Gardulf, A. (1991) · The Lancet · doi:10.1016/0140-6736(91)90147-h · Cited by 217
Subcutaneous immunoglobulin replacement in primary immunodeficiencies
Berger, M. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.02.002 · Cited by 193
Gardulf, A., Nicolay, U., la Cruz, O. A.-D., Bernatowska, E. A., Böck, A., Carvalho, B. C., Granert, C., Haag, S. F., de Rojas, D. H. F., Kiessling, P. C., et al. (2006) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9002-x · Cited by 187
Principles of Pharmacoeconomic Analysis of Drug Therapy
Freund, D. A., & Dittus, R. S. (1992) · PharmacoEconomics · doi:10.2165/00019053-199201010-00006 · Cited by 147
Hagan, J. B., Fasano, M. B., Spector, S. L., Wasserman, R. L., Melamed, I., Rojavin, M. A., Zenker, O., & Orange, J. S. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9423-4 · Cited by 132
Jolles, S. R. A., Bernatowska, E. A., de Gracia, J., Borte, M., Cristea, V., Peter, H. H., Belohradsky, B. H., Wahn, V., Neufang-Hueber, J., Zenker, O., et al. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.06.002 · Cited by 119
Subcutaneous Administration of IgG
Berger, M. (2008) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2008.07.002 · Cited by 113
Lee, D., Linker, R. A., Paulus, W., Schneider‐Gold, C., Chan, A., & Gold, R. (2007) · Muscle & Nerve · doi:10.1002/mus.20909 · Cited by 100
Högy, B., Keinecke, H.-O., & Borte, M. (2004) · The European Journal of Health Economics · doi:10.1007/s10198-004-0250-5 · Cited by 89
Nationwide Survey of Patients with Primary Immunodeficiency Diseases in Japan
Ishimura, M., Takada, H., Doi, T., Imai, K., Sasahara, Y., Kanegane, H., Nishikomori, R., Morio, T., Heike, T., Kobayashi, M., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9594-7 · Cited by 86
Self-citationNicolay, U., Haag, S. F., Eichmann, F., Herget, S., Spruck, D., & Gardulf, A. (2005) · Quality of Life Research · doi:10.1007/s11136-005-1746-x · Cited by 71
Lazzaro, C. R., Lopiano, L., & Cocito, D. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1632-9 · Cited by 55
Guideline for economic evaluation of healthcare technologies in Japan
Fukuda, T., Shiroiwa, T., Ikeda, S., Igarashi, A., Manabu, A., Ishida, H., Noto, S., Shin'ya, S., Hiroyuki, S., Shimozuma, K., et al. (2013) · 保健医療科学 · Cited by 55
Self-citationExpress Subcutaneous IgG Infusions: Decreased Time of Delivery with Maintained Safety
Hansen, S., Gustafson, R., Smith, C. I. E., & Gardulf, A. (2002) · Clinical Immunology · doi:10.1006/clim.2002.5215 · Cited by 54
Jolles, S. R. A., & Sleasman, J. W. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0036-y · Cited by 39
Kanegane, H., Imai, K., Yamada, M., Takada, H., Ariga, T., Bexon, M., Rojavin, M. A., Hu, W., Kobayashi, M., Lawo, J., et al. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-013-9985-z · Cited by 37
Self-citationThe Importance of Perspective in Pharmacoeconomic Analyses
Oderda, G. M. (2002) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/j354v16n04_07 · Cited by 11
Flagged first, then by citations
Research works printed but not linked: 1
- Ho C, Membe S, Cimon K,et al. Overview of subcutaneous versus intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis [Technology overview number 36]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2008. http://www.cadth.ca/index.php/en/publication/785. Accessed March 12, 2010.
Cited by
Sorted by citations
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Health-related quality of life in patients with primary immunodeficiency disease
Jiang, F., Torgerson, T. R., & Ayars, A. G. (2015) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-015-0092-y · Cited by 81
Cost and impact of early diagnosis in primary immunodeficiency disease: A literature review
Elsink, K., van Montfrans, J. M., van Gijn, M. E., Blom, M., van Hagen, P. M., Kuijpers, T. W., & Frederix, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108359 · Cited by 71
Mallick, R., Jolles, S. R. A., Kanegane, H., Agbor‐Tarh, D., & Rojavin, M. A. (2018) · Journal of Clinical Immunology · doi:10.1007/s10875-018-0562-3 · Cited by 30
Self-citationCost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
Alsina, L., Ronsano, J. B. M., Moral, P. M., Neth, O., Ortiz-Pica, M., Sánchez‐Ramón, S., Presa, M., Oyagüez, I., Casado, M. Á., & González‐Granado, L. I. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01378-x · Cited by 27
Pulvirenti, F., Cinetto, F., Pecoraro, A., Carrabba, M., Crescenzi, L., Neri, R., Bonanni, L., Fabio, G., Agostini, C., Spadaro, G., et al. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-0592-5 · Cited by 24
Windegger, T. M., Nghiem, S. H., Nguyen, K., Fung, Y. L., & Scuffham, P. (2020) · Blood transfusion · doi:10.2450/2019.0083-19 · Cited by 17
Bril, V., Lampe, J. B., Cooper, N., Kiessling, P. C., & Gardulf, A. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0171 · Cited by 13
The Choice between Intravenous and Subcutaneous Immunoglobulins: Aspects for Consideration
von Achenbach, C., Hevia, G., & von Gunten, S. (2022) · Pharmacology · doi:10.1159/000527655 · Cited by 10
Estructura, sistemas y análisis de costos de la atención médica hospitalaria
Benhumea, A. M. S., Villalobos, J. E. H., Jaimes, P. A. S., Benhumea, N. H. S., Manzur, M. Á. F., & Ortiz, A. D. A. (2015) · Medicina e Investigación · doi:10.1016/j.mei.2015.06.001 · Cited by 8
Shabaninejad, H., Asgharzadeh, A., Rezapour, A., & Rezaei, N. (2017) · Medical Journal of the Islamic Republic of Iran · doi:10.14196/mjiri.31.94 · Cited by 8
Tanikawa, T., Suzuki, R., Suzuki, T., Ishikawa, T., Yamashina, H., Tsuji, S., & Ogasawara, K. (2019) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2018.0244 · Cited by 6
Kan, A. K. C., Leung, G. M. K., Chiang, V., Au, E. Y. L., Lau, C. S., & Li, P. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984110 · Cited by 6
Desai, M. G., Kenney, J., & Pezalla, E. J. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2351165 · Cited by 5
Tichy, E. M., Prosser, B., & Doyle, D. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020938212 · Cited by 4
Więsik–Szewczyk, E., Kucharczyk, A., & Jahnz‐Różyk, K. (2014) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2014.2.5 · Cited by 3
Editorial: Immunoglobulin Therapy in the 21st Century – the Dark Side of the Moon
Farrugia, A., Visentini, M., & Quinti, I. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00436 · Cited by 3
Lim, B. W. D., & Latiff, A. H. A. (2024) · Asia Pacific Allergy · doi:10.5415/apallergy.0000000000000136 · Cited by 2
Ravasio, R., & Ripoli, S. (2023) · AboutOpen · doi:10.33393/ao.2023.2584 · Cited by 2
Estimating the Cost of Immunoglobulin Replacement Therapy in Primary Immunodeficiency Patients
Shabaninejad, H., Asgharzadeh, A., Rezaei, N., & Rezapour, A. (2017) · Iranian Journal of Pediatrics · doi:10.5812/ijp.6294 · Cited by 2
Hirata, Y., Sanada, Y., Takadera, K., Akimoto, R., Omameuda, T., Horiuchi, T., Okada, N., Wakiya, T., Onishi, Y., Sakuma, Y., et al. (2025) · Pediatric Transplantation · doi:10.1111/petr.70115 · Cited by 1
Netto, H. P., Ramires, Y., Aguiar, B. F., Lind, J., Gajardo, P., Ramos, M., & Rocha, J. L. L. (2020) · Jornal Brasileiro de Economia da Saúde · doi:10.21115/jbes.v12.n1.p32-8 · Cited by 1
Guerrero, C. G., Fernández-Polo, A., & Ronsano, J. B. M. (2017) · PharmacoEconomics Spanish Research Articles · doi:10.1007/s40277-016-0065-7
Advances in treating myasthenia gravis
Lee, I. J., & Wolfe, G. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00003-3
SCIG generates cost savings in Japan
(2014) · PharmacoEconomics & Outcomes News · doi:10.1007/s40274-014-1607-3
Metadata
- Authors
- Igarashi, A., Kanegane, H., Kobayashi, M., Miyawaki, T., & Tsutani, K.
- Affiliations
- The University of Tokyo (JP)
- University of Toyama (JP)
- CSL (Japan) (JP)
- Corresponding author
- Igarashi, Ataru
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 36
- Issue
- 11
- Pages
- 1616-1624
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2068790546
- Cited by
- 25
- References
- 24
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 3 · 2015: 3 · 2014: 2
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- CSL Behring
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- subcutaneous immunoglobulin, primary immunodeficiency, intravenous immunoglobulin, cost-minimization analysis, productivity loss, treatment costs, quality of life indicators, Japanese patients, quality of life
- MeSH terms
- Absenteeism, Adolescent, Adult, Child, Child, Preschool, Costs and Cost Analysis, Female, Hospitalization, Humans, Immunoglobulin G, Immunologic Deficiency Syndromes, Japan, Male, Middle Aged, Self Administration, Immunoglobulins, Intravenous, Cost Savings, Infusions, Subcutaneous, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
